Cantor Fitzgerald Suspends Neutral Rating on Crinetics Pharmaceuticals
Cantor Fitzgerald suspends Neutral rating on Crinetics Pharmaceuticals (NASDAQ:CRNX).
Stocks · News reference
Seven small-cap stocks have surged as much as 123% in early July on buyouts, FDA developments, refinancing deals and short squeezes.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Cantor Fitzgerald suspends Neutral rating on Crinetics Pharmaceuticals (NASDAQ:CRNX).
Filed: 2026-09-01 AccNo: 0001140361-26-035195 Size: 483 KB Item 1.02: Termination of a Material Definitive Agreement Item 2.01: Completion of Acquisition or Disposition of Assets Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Item 3.03: Material Modifications to Rights of Security Holders Item 5.01: Changes in Control of Registrant Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 9.01: Financial Statements and Exhibits
Stocks traded mixed at midday Friday as oil fell, yields neared 19-year highs, and Akamai jumped on a huge Anthropic deal.
Friday’s regular session has two sectors higher and nine lower, with growth and cyclical sectors split across the top three positions. The leaders are separated rather than clustered, with Technology and Industrials
IWM saw $3.3 billion in weekly outflows as the Russell 2000 fell 7.3% from mid-August, with rising Treasury yields adding pressure to small-cap stocks.
Three sectors are higher and eight are lower in Thursday’s regular session, with growth, cyclical and defensive sectors each represented among the top three. The leaders are separated rather than